This trial is evaluating whether Ixazomib will improve 6 primary outcomes in patients with Lymphoma. Measurement will happen over the course of Up to 5 years.
This trial requires 31 total participants across 1 different treatment group
This trial involves a single treatment. Ixazomib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"In the United States, multiple myeloma accounts for approximately 1% of all cancer deaths. Current treatments for multiple myeloma are highly effective and improving in quality of life and survival. Future therapies to be studied in multicenter clinical trials include bortezomib and other proteasome inhibitors; immunomodulators and biologic drugs; and vaccines or growth-factor-derived cytokines." - Anonymous Online Contributor
"Between 30,000 and 40,000 people get multiple myeloma a year in the United States, and more than 1,600 people a year in the State of Connecticut." - Anonymous Online Contributor
"Multiple myeloma is most commonly of the nonsecretory types. The incidence of multiple myeloma peaks in middle age and old age which is in excess of the incidence of chronic lymphocytic leukemia and smoldering multiple myeloma. Survival is poor especially with the nonsecretory type, but this can be improved by treatment of both types with chemotherapy and/or radiotherapy." - Anonymous Online Contributor
"Myeloma can be detected pre-symptomatically based on blood values such as a Bence Jones proteinuria, and by imaging such as radiographic abnormalities and increased serum globulin or paraprotein levels. In many patients at diagnosis, routine imaging studies often reveal lytic bone lesions that show no radiologic abnormality but are detectable with radionuclide imaging; bone lesions at diagnosis can be used as a substitute for imaging abnormalities on follow-up. Imaging abnormalities are most commonly found on the thorax but may also be found in the spine, and pelvis." - Anonymous Online Contributor
"MM is a disease that can be cured. However, recent disease-control advances have significantly improved the lives of patients with MM, and the outlook for those with symptomatic MM has improved." - Anonymous Online Contributor
"Many factors are known to be associated with increased risk of developing [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma), but in most cases multiple genetic and immunological defects are required for the disease to occur. The diagnosis of multiple myeloma is highly accurate but in many cases other diseases present with similar symptoms and signs because patients with the disease are too ill to be referred for evaluation. When patients with multiple myeloma are referred to a rheumatologist, a number of specific clinical scoring systems are utilized to help the diagnostic process. In view of the increasing longevity of patients with myeloma, the risk of the disease developing in others is of major importance." - Anonymous Online Contributor
"Overall we found that multiple myeloma is rare among the very elderly, i.e. the 10% aged 85 years and older (compared to less than 20% among age 70 years and younger) and the average age of diagnosis of multiple myeloma is 63.5 years (compared to 54 years for those aged 70 y and younger)." - Anonymous Online Contributor
"The genetic basis of MM remains largely undefined although studies have indicated certain genetic risk factors, such as 1PO, for which the disease has recently (2003) been shown to occur earlier in families with a higher prevalence of 1PO-MM. The findings underscore the possible importance of genetic interaction effects." - Anonymous Online Contributor
"As the overall use of ixzomib has become wider, the drug is used in combination with multiple other agents - most often with other proteasome inhibitors bortezomib or carfilzomib (e.g., with a pooled hazard ratio of 2.7, P<.01), a chemo therapy agent with proteasome inhibition (e.g., carboplatin, etoposide, or epirubicin with or without gemtuzumab ozogamicin), or platinum-based chemotherapeutics (e.g., cisplatin or carboplatin; hazard ratio = 2.8, P<.01)." - Anonymous Online Contributor
"Clinically used ixazomib is currently being studied in a Phase 3 trial as a single agent and in combination with vincristine and dexamethasone in patients with relapsed multiple myeloma. The first Phase 1 trial was completed in 2011. Results from a recent clinical trial and the Phase 3 trial will provide further information about safety and tolerability of ixazomib. Please [link to the clinicaltrials.gov website for the Phase 3 trial] if you have questions." - Anonymous Online Contributor
"There are several routes that the disease may spread, such as hematogenous (blood), lymphatic, and through the central nervous system. Most of the cases that would have been undetected on initial diagnosis because of lack of imaging have had a disease duration of 5 years or longer. Early detection of the disease will help the patient and physicians anticipate and manage treatment more effectively." - Anonymous Online Contributor
"Since the FDA approved approval of ixazomib, studies have shown the safety and efficacy of this agent as well as potential use in new treatment paradigms. These new findings provide an alternative approach to the management of MM." - Anonymous Online Contributor